Procalcitonin and C-Reactive Protein in Hospitalized Adult Patients With Community-Acquired Pneumonia or Exacerbation of Asthma or COPD  by Bafadhel, Mona et al.
1410 
CHEST Original Research
BIOMARKERS
Original Research
 Overuse of antibiotics is common and accelerates the development of drug resistance and hospital-
acquired infections. 1 The widespread use of antibiot-
ics over recent years has driven the increase in many 
drug-resistant bacteria, including that of methicillin-
resistant  Staphylococcus aureus and penicillin-resistant 
 Streptococcus pneumoniae . 2 Reliance on empirical 
broad-spectrum antibiotics in hospitals has led to 
the emergence and proliferation of the ribotype 027 
 Clostridium difﬁ cile strain. 3,4 Reducing antibiotic pre-
scription rates can reverse this trend, 5 so strategies 
that achieve reductions in antibiotic use in hospital-
ized patients are urgently required. 
 Community-acquired pneumonia and acute exacer-
bations of asthma and COPD represent a large propor-
tion of health-care use 6-8 and antibiotic prescription, 
with around 50% of all antibiotics in primary care 
being prescribed for acute respiratory infections. 9 
Patients hospitalized with community-acquired pneu-
monia have a mortality rate of up to 15%, 10 so rapid 
clinical assessment and treatment with empirical anti-
biotics is appropriate. 8 Viral infection causes the vast 
majority of exacerbations of asthma and is also an 
important cause of COPD exacerbations. 11,12 Although 
current treatment guidelines for asthma exacerbations 
do not recommend antimicrobials, 13,14 they are often 
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diagnostic accuracy of CRP in radiologically conﬁ rmed 
pneumonia failed to demonstrate sufﬁ cient sensitivity 
or speciﬁ city to be clinically useful; however, the 
reviewers acknowledged that the methodologic 
quality of the included studies was too weak to 
draw deﬁ nitive conclusions. 30 We hypothesized that 
the biomarkers CRP and procalcitonin have clinical 
usefulness in distinguishing between community-
acquired pneumonia (for which antibiotic therapy is 
indicated) from exacerbations of asthma (for which 
antibiotic therapy is not indicated) in hospitalized 
patients. The cut-offs derived from the receiver oper-
ator characteristic curves were used to propose when 
antibiotic therapy should/should not be given and 
to determine the potential reduction in antibiotic 
therapy prescription in patients with exacerbation of 
asthma and COPD. 
 Materials and Methods 
 Patients and Study Design 
 This was a prospective observational diagnostic accuracy 
study in patients recruited during the winter months of 2006 
to 2008 in two hospitals with acute medical admission units within 
the University Hospitals of Leicester NHS Trust, England . 
Patients were adults aged 18 to 93 years who were hospitalized 
with an  International Classiﬁ cation of Diseases ,  Tenth Revision 
discharge code 31 diagnosis of community-acquired pneumonia, 
or an exacerbation of asthma or COPD, who participated in a 
study of rapid near-patient and molecular diagnostic tests in 
acute respiratory illness. Patients with pneumonia were deﬁ ned 
as those with clinical signs and symptoms suggestive of lower 
respiratory infection and consolidation on plain chest radiograph. 
Patients with an acute exacerbation of asthma or COPD were 
deﬁ ned as those with an appropriate past medical history and 
acute respiratory symptoms without consolidation on chest radio-
graph or an alternative diagnosis. The study was approved by the 
Leices tershire, Northamptonshire, and Rutland Ethics Committee, 
and all patients gave informed written consent (05/Q2502/76). 
 Measurements 
 At entry into the study, demographic and clinical data were 
recorded. Data regarding antibiotic usage before and during the 
hospital admission, length of hospital stay, and clinical markers of 
severity using the modiﬁ ed Early Warning Score 32 and the pneu-
monia assessment tool CURB-65 (confusion, urea  . 7 mmol/L, 
respiratory rate  . 30 breaths/min, BP systolic  , 90 and dia-
stolic  , 60, age  . 65 years) 33 score as appropriate on admission 
were collected from case notes. All patients had a plain chest 
radiograph that was reviewed on admission by the admitting 
physician and subsequently reported by a consultant radiologist. 
All patients had venous blood collected at study entry, and 
qualitative detection of  S pneumoniae urinary antigen using 
the Binax assay. Where available, sputum for microbial culture 
was processed to identify potential pathogenic micro organisms 
( S pneumoniae , Moraxella catarrhalis ,  Haemophilus inﬂ uenzae , 
and  S aureus ) by routine techniques. 34 Procalcitonin and CRP 
assays were performed by personnel who were blind to the diag-
nosis. Unblinding was performed after data lock. 
prescribed. 15 Large systematic reviews of studies sug-
gest that antibiotics are not useful in mild to moderate 
exacerbations of COPD, 16-18 although in severe exac-
erbations there are reductions in rates of mechanical 
ventilation, short-term mortality, and readmission 
rates, 19 with which their use must be balanced against 
the risk of developing severe side effects such as 
 C difﬁ cile infection. 
 Recent strategies to reduce antibiotic overuse 
have included the development of biomarker-directed 
treatment algorithms wherein antibiotics are given 
or withheld depending on the level of biomarkers 
measured in the blood. Procalcitonin-guided therapy 
has been effective in reducing antibiotic use by approx-
imately 50% in hospitalized patients presenting with 
acute lower respiratory tract infection symptoms 
(including patients with community-acquired pneumo-
nia, exacerbations of COPD, and exacerbations of 
asthma) 20,21 and by up to 40% in a selected group of 
patients with exacerbation of COPD. 22 In a study of 
procalcitonin-guided antibiotic therapy for hospi-
talized patients with community-acquired pneumo-
nia, 15% of patients had antibiotics withheld on 
admission and overall antibiotic exposure was reduced 
in the order of 50%. 23 In all of these randomized 
controlled studies there was no increase in adverse 
events among patients who had antibiotics withheld. 
 Measurement of C-reactive protein (CRP) is inex-
pensive and widely available. CRP levels are elevated 
in patients with community-acquired pneumonia 
compared with healthy control subjects. 24 Persistently 
elevated levels following treatment are associated with 
complications and treatment failure, 24-28 whereas a 
decline in concentration is associated with recovery. 29 
A previous systematic review of trials examining the 
 Manuscript received July 9, 2010; revision accepted September 25, 
2010 . 
 Afﬁ liations: From the Institute for Lung Health (Drs Bafadhel 
and Brightling and Ms Reid), and the Department of Infection, 
Immunity, and Inﬂ ammation (Drs Bafadhel, Barer, Nicholson, and 
Brightling and Mss Medina and Batham), University of Leicester; 
and the Department of Infectious Disease (Drs Clark and Nicholson 
and Ms Batham), University Hospitals of Leicester NHS Trust, 
Leicester, England. 
 Drs Bafadhel and Clark contributed equally to this article. 
 Funding/Support:  This study was funded by a Health Technol-
ogy Assessment grant [03/39/18] (Dr Nicholson) and Wellcome 
Senior Clinical Fellowship [03/91/68] (Dr Brightling ). 
 Correspondence to: Christopher E. Brightling, PhD, FCCP, 
Institute for Lung Health, University of Leicester, Department of 
Infection, Immunity, and Inﬂ ammation, Clinical Sciences Wing, 
Glenfield Hospital, Groby Rd, Leicester, LE3 9QP, England; 
e-mail: ceb17@le.ac.uk 
 © 2011 American College of Chest Physicians. This is an 
Open Access article distributed under the terms of the Creative 
Commons Attribution-Noncommercial License ( http://creative
commons.org/licenses/by-nc/3.0/ ), which permits unrestricted use, 
distribution, and reproduction in any medium, provided the origi-
nal work is properly cited. Information for commercial entities is 
available online ( http://www.chestpubs.org/site/misc/reprints.xhtml ). 
 DOI: 10.1378/chest.10-1747 
 © 2011 American College of Chest Physicians
 by Kimberly Henricks on June 8, 2011chestjournal.chestpubs.orgDownloaded from 
1412 Original Research
validated in previous trials to guide antibiotic therapy (procal-
citonin  , 0.1,  bacterial infection very unlikely, antibiotic use 
strongly discouraged; procalcitonin  , 0.25, bacterial infec-
tion unlikely, antibiotic use discouraged; pro calcitonin  . 0.25 
bacterial infection likely, anti biotic use suggested). 20-23 
 C-Reactive Protein 
 CRP was measured from 25  m L of serum using an automated 
clinical analyzer (Abbott Architect ci8200; Abbott Laboratories; 
 Procalcitonin 
 Procalcitonin was measured in duplicate from 50  m L of serum 
using a time-resolved amplified cryptate emission technology 
assay (Kryptor TRACE PCT; Brahms AG; Cambridge, England ). 
The lower limit of detection is 0.02 ng/mL and concentrations 
below this limit of detection were assigned as zero. The assay 
functional sensitivity was 0.06 ng/mL, and the intraassay coefﬁ -
cient at a sample concentration of 0.2 ng/mL was 10%. Threshold 
values of 0.1 and 0.25 ng/mL were used as these have been 
 Figure 1. Trial proﬁ le for patients enrolled in the study. CXR  5 chest radiograph. 
 Table 1— Demographic and Clinical Data From Patients Admitted With Pneumonia, 
Exacerbation of Asthma, or Exacerbation of COPD 
Variable Pneumonia Asthma Exacerbation COPD Exacerbation  P Value
No. 62 96 161 …
Male, % 63 37 48 .001
Age, a y 63 (24-93) 41 (18-84) 69 (39-93)  , .001
Antibiotics given, % 100 57 76  , .001
IV antibiotics given, % 74 10 18  , .001
Antibiotics prior to admission, % 25 35 35 .34
 Streptococcus pneumoniae urinary antigen positive, % 29 2 5  , .001
Length of stay, a d 6 (1-40) 3 (1-19) 5 (1-31)  , .001
Temperature, b °C 37.1 (1.1) 36.8 (0.9) 36.6 (0.8)  , .001
Respiratory rate, b 22 (7) 22 (7) 23 (6) .95
Systolic BP, mm Hg 120 (3) 132 (2) 134 (2)  , .001
Pulse rate, beats/min 98 (2) 100 (2) 95 (1) .08
Modiﬁ ed early warning score a 3 (0-7) 3 (0-7) 2 (0-8) .06
Blood leukocytes, b  3 0 9 cells/L 14.1 (7.5) 10.8 (4.3) 10.1 (4.9)  , .001
Blood neutrophils, b  3 10 9 cells/L 12.4 (7.2) 7.7 (4.4) 7.5 (4.7)  , .001
CRP, b mg/L 191 (159) 9 (21) 16 (34)  , .001
Procalcitonin, b ng/mL 1.27 (2.36) 0.03 (0.04) 0.05 (0.06)  , .001
Data presented as mean (SE of mean), unless stated. CRP  5 C-reactive protein.
 a Mean (range).
 b Median (interquartile range).
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 Figure 2. Box and whisker plots for patients admitted with exacerbation of asthma, COPD, and pneu-
monia for the biomarkers procalcitonin and C-reactive protein. The horizontal bar represents the 
median; the box length represents the interquartile range. Outliers are identiﬁ ed by   (1.5  3 the inter-
quartile range) and * (3  3 the interquartile range). 
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Abbott Park, Illinois), which has a lower limit of detection of 
5 mg/L. The intraassay and interassay variability was  , 10%. CRP 
was measured in all patients as part of routine clinical care. 
 Statistical Analysis 
 Statistical analyses were performed using PRISM, version 4 
(GraphPad Software Inc; La Jolla, California) and SPSS, version 16 
(SPSS, Inc; Chicago, Illinois). Parametric data were expressed as 
mean and SE of the mean, and nonparametric data were described 
as median and interquartile range. One-way analysis of variance 
and the Kruskal-Wallis test were used for across- and between-
group comparisons for parametric and nonparametric data, respec-
tively; post hoc analysis was performed using Tukey or Dunn 
comparison tests. Correlations were assessed by Pearson correla-
tion coefﬁ cient ( r ) and Spearman rank correlation coefﬁ cient ( r s) 
for parametric and nonparametric data. The Clopper-Pearson 
method was used to calculate CIs for proportions. To determine 
the diagnostic accuracy of the biomarkers, receiver operating 
characteristic curves and area under the curve with 95% CIs 
for patients with asthma exacerbation (antibiotics not required) 
vs pneumonia (deﬁ nite antibiotics required) were plotted. The 
Youden index was used to identify the optimal cut-off point on 
the receiver operator characteristic curve with equal weighting of 
sensitivity and speciﬁ city 35 and to determine the potential reduc-
tion in antibiotic therapy in hospitalized patients. A  P value  , .05 
was taken as the threshold for statistical signiﬁ cance. 
 Results 
 We studied 319 patients: 62 with pneumonia, 
96 with acute exacerbation of asthma, and 161 with 
exacerbation of COPD ( Fig 1 ,  Table 1 ). Sputum cul-
ture for a potential pathogenic microorganism was 
detected in 29% and 44% of patients with pneumonia 
and COPD on admission. Urinary pneumococcal anti-
gen was positive in 29% of patients with pneumonia. 
 Patients with pneumonia had higher procalcitonin 
and CRP levels than those with COPD ( P  , .0001) or 
asthma ( P  , .0001) ( Fig 2 ). The concentration of pro-
calcitonin was below the limit of detection in 24%, 6%, 
and 2% of patients with asthma, COPD, and pneu-
monia, respectively. The median CURB-65 score was 
1 (interquartile range 1). All of the patients with pneu-
monia received antibiotic therapy, whereas 57% and 
76% of patients with asthma and COPD, respec-
tively, received antibiotics while hospitalized. 
 Procalcitonin and CRP levels were strongly corre-
lated ( r s  5 0.56,  P  , .0001). The area under the receiver 
operator characteristic curve (95% CI) for the clinical 
parameters of peripheral neutrophil counts, temper-
ature on admission, and modiﬁ ed early warning 
score 32 for distinguishing between patients with pneu-
monia (antibiotics required) and exacerbations of 
asthma (antibiotics not required) were 0.77 (0.69-0.85), 
0.65 (0.56-0.74), and 0.54 (0.44-0.63), respectively 
( Fig 3 ). The area under the receiver operator charac-
teristic curve (95% CI) for procalcitonin and CRP was 
0.93 (0.88-0.98) and 0.96 (0.93-1.00), whereas the 
product of procalcitonin and CRP (PCT  3 CRP) 
yielded a value of 0.98 (0.96-1.00) ( Fig 4 ). 
 Using the receiver operator characteristic 
curve to identify the optimum CRP threshold 
value, a level of  . 48 mg/L had a sensitivity 
 Figure 3. Receiver operator characteristic curve distinguishing between patients with pneumonia 
(antibiotics required) and exacerbations of asthma (antibiotics not required) for peripheral neutrophils, tem-
perature, and modiﬁ ed early warning score. AUC  5 area under the receiver operator characteristic curve. 
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 The proportion of patients who would have received 
antibiotics if biomarker-directed therapy was used, 
using the threshold values for procalcitonin of 0.1 and 
0.25 ng/mL and for CRP of 10, 30, and 48 mg/L, is 
shown in  Table 2 . Using a procalcitonin threshold 
value of  . 0.25 ng/mL to guide antibiotic therapy, anti-
biotic use would be reduced from 57% to 4% in 
patients with exacerbation of asthma (ie, a reduction 
in antibiotic usage of 93%; 95% CI, 88%-98%), from 
76% to 7% in patients with exacerbation of COPD 
(ie, a reduction of 91%; 95% CI, 87%-95%) and from 
100% to 73% in those with pneumonia (ie, a reduction 
of 27%; 95% CI 17%-40%). Using a CRP threshold 
of 91% (95% CI, 80%-97%) and speciﬁ city of 
93% (95% CI, 86%-98%) for identifying patients with 
pneumonia. The optimal threshold value calculated 
for procalcitonin was 0.08 ng/mL, of which a level 
greater than this had a sensitivity of 89% (95% CI, 
78%-95%) and speciﬁ city of 78% (95% CI, 72%-82%) 
for identifying patients with pneumonia. 
 Thirty-three percent of all patients received antibi-
otics prior to admission. The area under the receiver 
operator characteristic curve (95% CI) was not different 
between the patients who did or did not receive prior 
antibiotics for CRP (0.96 [0.92-1.00] vs 0.94 [0.89-0.99] 
or procalcitonin (0.96 [0.89-1.00] vs 0.92 [0.83-1.00]). 
 Figure 4. Receiver operator characteristic curve for distinguishing between patients with pneumonia 
(antibiotics required) and exacerbations of asthma (antibiotics not required) for PCT.CRP, PCT, and 
CRP. CRP  5 C-reactive protein; PCT  5 procalcitonin; PCT.CRP  5 procalcitonin C-reactive protein 
product. See Figure 3 for expansion of the other abbrevation. 
 Table 2— Proportion of Patients Receiving Antibiotic Therapy on Admission and Proportion Who Would Have 
Received Antibiotic Therapy if Biomarker-Directed Therapy Were Used With the Relevant Threshold Values 
for PCT and CRP 
Diagnosis
Proportions Actually 
Treated
Proportions Who Would Have Been Treated if Biomarker-Directed Therapy Were Used
PCT, ng/mL CRP, mg/L
0.1 Threshold 
Value
0.25 Threshold 
Value
10 Threshold 
Value
30 Threshold 
Value
48 Threshold 
Value
Asthma, % 57 9 4 43 15 7
 (95% CI) (46-67) (4-16) (1-11) (33-54) (9-24) (2-14)
COPD, % 76 24 7 59 32 21
 (95% CI) (68-82) (17-31) (4-13) (51-67) (25-40) (15-28)
Pneumonia,% 100 82 73 95 91 91
 (95% CI) (96-100) (70-91) (60-83) (85-99) (80-97) (80-97)
PCT  5 procalcitonin. See Table 1 for expansion of other abbreviation.
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primary care 39 and interestingly has similar accuracy to 
studies looking at infected and noninfected patients. 40,41 
The threshold levels generated in our study to guide 
antibiotic therapy could lead to safe reductions in anti-
biotic usage among patients hospitalized with exacer-
bations of airways disease. Using the threshold level 
for CRP of  . 48 mg/L to guide antibiotic therapy in 
acute respiratory illness, a small proportion of patients 
with pneumonia would not have been treated. How-
ever, withholding antibiotics from those patients with 
low levels of biomarkers was not associated with 
adverse outcomes. 23 
 One possible limitation of this study is the use of 
the  International Classiﬁ cation of Diseases ,  Tenth 
Revision classiﬁ cation of disease coding 31 to deﬁ ne 
diagnosis and enrollment. Although coding can be inac-
curate, we used additional clinical and radiographic 
evidence to improve diagnostic accuracy and con-
ﬁ dence that our clinical groups represent those 
encountered in clinical practice. A further limitation 
is the lack of etiologic data to distinguish patients with 
a viral or bacterial cause for the lower respiratory tract 
illness. However, it is known that bacteria are detected 
in less than one-half of pneumonias, 42 whereas isola-
tion of viruses does not exclude bacterial coinfection 
and the need for antibiotics. By applying a clinical 
diagnosis to our cohort and using blinded compari-
sons, we evaluated procalcitonin and CRP under 
realistic clinical practice conditions. Our study was 
cross-sectional in nature so we cannot discount the 
possibility of subsequent clinical deterioration and 
delayed onset of pneumonia during admission, 
although it is notable that this phenomenon was not 
observed in the procalcitonin studies. 20-22 Further-
more, approximately 30% of our patients received 
antibiotics prior to admission that could potentially 
affect the levels of biomarkers measured. Interest-
ingly, we found that this did not affect the usefulness 
of CRP, and marginally affected levels of procalci-
tonin, although preadmission antibiotic therapy has 
been shown not to affect the effectiveness or safety of 
biomarker-directed therapy. 20-23 
 In conclusion, there is an urgent need to reduce 
antibiotic prescription in patients hospitalized with 
acute respiratory illness. Our study demonstrates that 
CRP has at least equal accuracy for the detection 
of pneumonia and could be used in a similar way to 
procalcitonin to guide antibiotic therapy in hospital-
ized patients with lower respiratory tract infection, 
although this would require further evaluation in 
large prospective interventional randomized control 
studies. 
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value of  . 48 mg/L to guide antibiotic therapy, anti-
biotic use would be reduced from 57% to 7% (ie, a 
reduction of 88%; 95% CI, 76%-95%) in patients with 
asthma, from 76% to 18% (ie, a reduction of 76%; 
95% CI, 65%-85%) in patients with exacerbation of 
COPD, and from 100% to 91% (ie, a reduction of 9%; 
95% CI, 2%-18%) in patients with pneumonia. 
 Discussion 
 We have shown that the biomarkers procalcitonin 
and CRP are correlated and elevated in patients with 
pneumonia compared with patients with exacerba-
tions of asthma and COPD, suggesting that they can 
usefully guide antibiotic usage. We have shown that 
both procalcitonin and CRP are more reliable in distin-
guishing between acute respiratory illnesses than the 
peripheral neutrophil count and clinical severity score. In 
this large study of common respiratory disease presen-
tations we observed a high antibiotic prescription rate 
in patients with asthma contrary to recommendations 
and a high level of antibiotic use in exacerbations of 
COPD. 13,14 
 Our ﬁ ndings support the view that biomarker-
directed antibiotic therapy would lead to a marked 
reduction in antibiotic use in patients with exacerba-
tions of asthma and COPD. There is a clinical need to 
reduce unnecessary antibiotic use in both primary and 
secondary care. Biomarker-directed therapy aims to 
reduce bacterial drug resistance and the high mor-
bidity and mortality associated with hospital-acquired 
infections. 1,2 Clinical trials that have used procalcitonin 
to guide antibiotic therapy for patients with symp-
toms suggestive of a lower respiratory tract infection, 
including patients with COPD, have shown that a 
biomarker-driven algorithm can cut antibiotic prescrib-
ing signiﬁ cantly and that this can be achieved without 
any increase in adverse events or treatment failures. 20-22 
 Our study also highlights the usefulness of CRP 
and procalcitonin in differentiating pneumonia from 
COPD and asthma. Although a recent study of the 
usefulness of biomarkers in predicting bacteremia in 
patients with community-acquired pneumonia sug-
gested a superior efﬁ cacy of procalcitonin compared 
with CRP, 36 it has been shown that CRP compared 
with procalcitonin is a better predictor of treatment 
responses in exacerbations of COPD. 19 Furthermore, 
our ﬁ ndings concur with those of other recent stud-
ies showing that CRP can distinguish patients with 
pneumonia from exacerbation of COPD and heart 
failure. 37,38 
 Our observations suggest that CRP could be used 
to guide antibiotic prescription in patients hospital-
ized with acute lower respiratory tract symptoms, 
which is similar to ﬁ ndings observed in a large cohort 
of patients with lower respiratory tract symptoms in 
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